NASDAQ : ILMN

Illumina, Inc.

$194.09 USD

-$2.77 (-1.41%)

Volume
1.3M
Average Volume
1.88M
Market Capitalization
$29.37B
P/E Ratio
35.03
Dividend Yield
0.00%
Price Target
$170.00
Year High
$199.14
Year Low
$88.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.75
Company Overview

NASDAQ

Jacob Thaysen

Medical - Diagnostics & Research

Healthcare

ILMN

8600

US

USD

https://www.illumina.com

858 202 4500

452327109

0001110803

Liquidity Metrics

0.95

1.75

1.36

0.70

0.00

Sales & Valuation

$4.34B

6.69

11.10

29.69

6.46

Profitability

$5.45

$850M

19.43%

24.16%

33.99%

13.01%

P/E Metrics

35.03

0.27

0.27

Analyst Price Target & Rating

$170.00

$210.00

$122.00

Neutral

3/5

50 Analysts

14.17%

Financial Health Scores

5.95

7/9

$1.17B

$6.56B

$3.88B

$1.16B

Key Metrics (TTM)

$30.82B

7.02

21.52

1.75

33.99%

13.26%

2.87%

3.37%

$46.84

161 days

Company Executives
Name Title
Steven Barnard Chief Technology Officer
Jacob Thaysen CEO, Interim Chief Commercial Officer & Director
Scott Davies Chief Legal Officer & Secretary
Scott Ericksen Vice President & Chief Accounting Officer
Patricia Leckman Senior Vice President & Chief People Officer
Mark Field Chief Information Officer
Ankur Dhingra Chief Financial Officer
Conor Noel McNamara Vice President of Investor Relations
Stephanie Campos President
Jakob Wedel Chief Strategy & Corporate Development Officer
Kevin Carl Pegels Chief of Global Operations
Poll Results

No votes yet today — be the first to share your view!

About Illumina, Inc. (NASDAQ:ILMN) Stock

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, ... universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

EXEL vs. ILMN: Which Stock Is the Better Value Option?

2026-07-24 12:41:18

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?

Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown

2026-07-22 06:00:00

CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in “Hallucinating Value: Healthcare's AI Narrative.” The findings come from the Fishbone Health.

Amova Asset Management Americas Inc. Sells 165,333 Shares of Illumina, Inc. $ILMN

2026-07-21 04:21:05

Amova Asset Management Americas Inc. trimmed its position in Illumina, Inc. (NASDAQ: ILMN) by 18.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 721,532 shares of the life sciences company's stock after selling 165,333 shares during the period. Illumina comprises 1.3% of Amova

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

2026-07-20 11:51:04

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Illumina expands Billion Cell Atlas program with new AI drug developers

2026-07-16 12:00:00

Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.

Here's Why Illumina (ILMN) is a Strong Growth Stock

2026-07-16 10:46:04

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

2026-07-09 16:05:00

SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Stocks Look Shaky, But This Sector is Booming (Biotech)

2026-07-09 14:06:06

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

Frequently Asked Questions

What is the current Illumina, Inc. (ILMN) stock price?

Illumina, Inc.(NASDAQ:ILMN) stock price is $194.09 in the last trading session. During the trading session, ILMN stock reached the peak price of $199.14 while $88 was the lowest point it dropped to. The percentage change in ILMN stock occurred in the recent session was --1.41% while the dollar amount for the price change in ILMN stock was -$2.77.

ILMN's industry and sector of operation?

The NASDAQ listed ILMN is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of ILMN?

Steven Barnard | Chief Technology Officer
Jacob Thaysen | CEO, Interim Chief Commercial Officer & Director
Scott Davies | Chief Legal Officer & Secretary
Scott Ericksen | Vice President & Chief Accounting Officer
Patricia Leckman | Senior Vice President & Chief People Officer

How many employees does ILMN have?

Number of ILMN employees currently stands at 8600. ILMN operates from 5200 Illumina Way, San Diego, CA 92122, US.

Link for ILMN official website?

Official Website of ILMN is: https://www.illumina.com

How do I contact ILMN?

ILMN could be contacted at phone #858 202 4500 and can also be accessed through its website. ILMN operates from 5200 Illumina Way, San Diego, CA 92122, US.

How many shares of ILMN are traded daily?

The average number of ILMN shares traded daily for last 3 months was 1.88M.

What is the market cap of ILMN currently?

The market value of ILMN currently stands at $29.37B with its latest stock price at $194.09